Seeking Alpha


Send Message
View as an RSS Feed
View candooman's Comments BY TICKER:
Latest  |  Highest rated
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    This is too small a trial to say that since it just slows down the disease progression, it is not good. The trial was done in 3 cohorts. The results presented were for the entire trial. The results for the higher dosed patients were not discussed (one person in the Q&A asked this question and did not get an answer). Could it have been that the progression of the disease was stopped ... or maybe even slightly reversed? Could a multiple dosage reverse the progression of ALS? It is too early to make definitive conclusions.
    Jan 7, 2015. 05:20 PM | 1 Like Like |Link to Comment
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    CUR reports on results on Tue Jan 13th, 9 AM. We will see, perhaps, if BCLI is better than CUR, or, is it an apple and orange comparison -- both taste good!
    Jan 7, 2015. 05:11 PM | Likes Like |Link to Comment
  • Sirius Is Seriously Going Higher [View article]
    I agree with you SF. Lowest I got was 0.08 and a lot more between 0.11 and 0.15. Got more later to average out in the mid 0.40s. Fortunately I only have a couple hundreds at $4+ from 2008 -- pre-Feb 2009.

    As you noted, very few shares were traded at 0.05.
    Jan 2, 2015. 01:27 PM | Likes Like |Link to Comment
  • Sirius Is Seriously Going Higher [View article]
    If not for Malone, err, err, err Ergen better? He would have gotten SIRI for nothing and thrown us shareholders all out. Yup, Malone got a good chunk of SIRI but then, we got a lot of capital gains.... so thanks Mr Malone.
    Jan 2, 2015. 01:12 PM | 3 Likes Like |Link to Comment
  • Sirius XM Short Interest Continues To Decline [View article]
    Good article CN! Thanks.
    Here is to a Prosperous New Year and a rising SIRIUSXM stock!
    Initial December car sales reports shows a good jump.
    Dec 30, 2014. 10:59 AM | Likes Like |Link to Comment
  • Cell Therapy 2015: With Maturity Comes Promise [View article]
    OCAT (formerly ACTC) is the only company with FDA approved treatment using hESC. It has successfully finished Ph1/2 AMD and SMD trials with strong indications of efficacy at the higher cell dosage and is about to start Ph 2. I believe they have FDA approval to treat AMD of younger patients who most likely will get better results than their trial patients who were in their 80s and have had AMD for many many years.

    I do not understand why the author did not mention this pioneering company.
    Dec 24, 2014. 12:55 PM | Likes Like |Link to Comment
  • Sirius XM: Thoughts On Manipulation [View article]
    Thank you Prof Faulkner, for providing a clear explanation of the stock price staying in a narrow range in spite of hundreds of millions of buybacks..... and how Malone was able to control his takeover of SIRI, all without costing him too much money. It was a big puzzle to me. After December 1st, will we see much lower number of shorts?
    Nov 28, 2014. 05:44 PM | 1 Like Like |Link to Comment
  • Athersys Could Benefit Immensely From Japan Reimbursement On Stroke [View article]
    All companies that treat diseases with cells will benefit from this new Japanese law. Some companies are in a more advanced state of Phase II trials in the US and have shown efficacy in their completed Phase I trials. A couple of companies that come to mind that will benefit from this new Japanese law, should they chose to do some trials in Japan are OCAT and CUR. Because of the extra cost and limited resources, they may opt in only after they have received FDA approvals, which will make it easy to enter the Japanese market.
    Nov 26, 2014. 12:48 PM | 3 Likes Like |Link to Comment
  • InVivo Therapeutics [View news story]
    Exdivy, further to your comments. All 5 study cases will vary depending upon the degree of injury. Of 5 study subjects 2-3 may succeed. Success of first case will shoot stock straight up (around end of Jan 2015), second could fail - bring it back all the way down. Other 3 will be 50/50. Of those treatment that fail or be deemed ineffective, I believe researchers will learn that of those ineffective cases, it could succeed if stem cells were added with the scaffolding.

    This is where CUR comes in. The area NVIV treated could be reopened, CUR's cells added - and this could be the cure. We will know the viability of this idea from the results of CUR's current ongoing trial of those who suffered 1-2 years post injury.

    However, CUR's cells could very well make most, if not all (depend on extent of injuries) NVIV treatments succeed if cells are added right away upon treatment - the first time.... my opinion. 2015 will be a very exciting year of NVIV and CUR!
    Nov 13, 2014. 09:41 AM | 2 Likes Like |Link to Comment
  • Axion Power's IPO Crash: An Opportunity To Buy? [View article]
    I suggest you guys read the many blogs John Peterson wrote two-three years ago explaining the workings of PcB batteries .... correct term is Hybrid batteries since it combines parts of the regular lead acid battery with a capacitor. JP's blogs are pretty clear and extensive. Search them here on Seeking Alpha.
    Nov 10, 2014. 10:54 AM | 2 Likes Like |Link to Comment
  • Axion Power's IPO Crash: An Opportunity To Buy? [View article]
    A/C is needed by the controls and inverter circuit not by the battery. This is true for the CUBE but not for trucks and cars since they use DC power not AC.
    Nov 10, 2014. 10:40 AM | 3 Likes Like |Link to Comment
  • Advanced Cell Technology Is Scaling Up Its Blood Program [View article]
    I have been wondering how long after the peer reviewed paper on platelets was publish last week before a SA author would write about it. Thanks Biocell for writing a very good article.

    This is a many times bigger pie than AMD and SMD and There is a high probability its development will be funded by the Defense Department or Homeland Security to the tune of many millions of dollars. If they do, then there will be no dilution, a big gain for ACTC. Some big pharma, seeing the potential, may buy ACTC (I hope not) -- before our government offers funding.

    I do not expect anything will happen until perhaps the beginning of the 2015 when the new CCO's work will bear fruit. In the meantime, Management can give us a clue at the Nov 12 Shareholder's Meeting.
    Oct 27, 2014. 12:19 PM | Likes Like |Link to Comment
  • New commercial chief at Advanced Cell Tech [View news story]
    Wotton certainly sees the high potential and wants to move forward - now!

    I'm long ACTC too.
    Oct 21, 2014. 10:25 AM | 2 Likes Like |Link to Comment
  • New commercial chief at Advanced Cell Tech [View news story]
    And with military support, they will finance the effort and be non dilutive. ACTC will still need a tie up with big pharma for the marketing and distribution of the product, perhaps, even the manufacture. ACTC is a very small company and does not have the resources and expertise in this area. The one possible drawback with seeking military funding is the availability of funds. The Defense Dept has funds for this kind of effort but the question is, hare there any left to spend?
    Oct 21, 2014. 10:22 AM | Likes Like |Link to Comment
  • New commercial chief at Advanced Cell Tech [View news story]
    The only thing they did with the iPS cells is strip it of the gene that causes rejection. Otherwise, all normal functions are left intact to do what it normally does. What is not clear to me is what was the original source of the iPS cells which are adult cells. Did ACTC have to differentiate it to become a platelet? This could require a trial to make sure it stays as a platelet and nothing more.

    The previous ACTC Management mentioned that they were shelving this project until they get the AMD and SMD approved so they will have money to spend on this platelet and other things on their plate. On the other hand, current management I believe, want to get this platelet line developed now. To do this, they need an experienced hand who can lead the effort which will be quite considerable. One which will require considerable time and effort is making a deal with a pharma company big that has world wide operations is needed. The partnership will require the big pharma company to pay for the trials. The deal could be made non-dilutive if ACTC gives a license to sell the platelets on an exclusive basis for say ten years after FDA approval. I am just laying out one scenario and there will be many. Hence, the hiring of this Commercial VP. This is my take.
    Oct 21, 2014. 10:11 AM | Likes Like |Link to Comment